Caribou Biosciences, Inc. (NASDAQ:CRBU) Shares Sold by Point72 Asset Management L.P.

Point72 Asset Management L.P. cut its holdings in Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) by 54.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,024,989 shares of the company's stock after selling 1,206,429 shares during the quarter. Point72 Asset Management L.P. owned about 1.13% of Caribou Biosciences worth $1,630,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in CRBU. Nuveen Asset Management LLC grew its holdings in shares of Caribou Biosciences by 23.6% during the fourth quarter. Nuveen Asset Management LLC now owns 330,831 shares of the company's stock worth $526,000 after buying an additional 63,096 shares during the last quarter. Millennium Management LLC lifted its position in Caribou Biosciences by 52.9% during the 4th quarter. Millennium Management LLC now owns 859,825 shares of the company's stock worth $1,367,000 after acquiring an additional 297,351 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Caribou Biosciences by 4.9% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 176,654 shares of the company's stock valued at $281,000 after purchasing an additional 8,199 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in shares of Caribou Biosciences in the fourth quarter valued at approximately $1,921,000. Finally, Ameriprise Financial Inc. purchased a new stake in shares of Caribou Biosciences during the fourth quarter worth approximately $649,000. 77.51% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a "buy" rating and set a $3.00 price target (down from $9.00) on shares of Caribou Biosciences in a report on Monday, April 28th. Four investment analysts have rated the stock with a buy rating, According to MarketBeat, Caribou Biosciences currently has a consensus rating of "Buy" and an average price target of $7.40.

Caribou Biosciences Stock Down 7.7%

NASDAQ CRBU opened at $1.02 on Thursday. The stock has a market capitalization of $94.40 million, a P/E ratio of -0.62 and a beta of 2.36. Caribou Biosciences, Inc. has a 52-week low of $0.66 and a 52-week high of $3.19. The firm has a 50-day moving average price of $0.86 and a 200 day moving average price of $1.40.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.43) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.43). The business had revenue of $2.35 million during the quarter, compared to the consensus estimate of $1.48 million. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. On average, equities research analysts expect that Caribou Biosciences, Inc. will post -1.64 earnings per share for the current fiscal year.

Caribou Biosciences Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.

Want to see what other hedge funds are holding CRBU? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.